Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA4 | P22748 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.58 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15206243 | 0.96 | TRPV1 (0.62) | TRPV1APPBCHEACHECHRM1 | |
| Mabuprofen SCHEMBL51633 | 0.91 | CHRM1 (0.67) | TRPV1APPBCHEACHECHRM1 | |
| SCHEMBL4431747 | 0.87 | APP (0.63) | TRPV1APPBCHEACHECHRM1 | |
| SCHEMBL3817985 | 0.87 | APP (0.63) | TRPV1APPBCHEACHECHRM1 | |
| SCHEMBL13254990 | 0.87 | TRPV1 (0.64) | TRPV1APPBCHEACHECHRM1 | |
| SCHEMBL14069293 | 0.87 | TRPV1 (0.64) | TRPV1APPBCHEACHECHRM1 | |
| SCHEMBL13361030 | 0.87 | TRPV1 (0.62) | TRPV1APPBCHEACHECHRM1 | |
| SCHEMBL31119849 | 0.87 | TRPV1 (0.66) | TRPV1APPBCHEACHECHRM1 | |
| Hydrochloric Acid SCHEMBL4743230 | 0.86 | APP (0.62) | TRPV1APPBCHEACHECHRM1 | |
| Hydrochloric Acid SCHEMBL4743234 | 0.86 | APP (0.62) | TRPV1APPBCHEACHECHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315834-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315834-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF | HMGB1, PTGES, FDPS | TRPV1 23/4885APP 588/4885BCHE 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.